Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKT cells plus gefitinib for EGFR-mutant advanced non-small cell lung cancer
ChiCTR-IIR-17013471Phase 2Not yet recruiting
- Sponsor
- Jiangsu University Affiliated Hospital
- Start
- Jul 2017
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous natural killer T cells and gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu University Affiliated Hospital. Primary endpoint: progression-free survival. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
autologous natural killer T cellsgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-17013471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013471.